Meeting
2012 ASCO Annual Meeting
Baseline albumin (b-alb) as a potential predictive biomarker for the efficacy of bevacizumab (B) therapy (tx) in patients (pts) with advanced pancreas cancer (APCA): A comparative analysis.
Authors
Ludmila Katherine Martin
The Ohio State University Medical Center, Columbus, OH
Ludmila Katherine Martin , Susan Michelle Geyer , Anissa Bingman , Mark M. Zalupski , Tanios S. Bekaii-Saab
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Citation
J Clin Oncol 30, 2012 (suppl; abstr 4039)
DOI
10.1200/jco.2012.30.15_suppl.4039
Abstract #
4039
Poster Bd #
40F
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance).
First Author: Jeffrey Melson Clarke
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line chemotherapy regimens associated with survival in advanced pancreatic cancer: A Mexican single-center, real-world study.
First Author: Marytere Herrera
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Final clinical outcome and biomarker analysis of sintilimab plus a bevacizumab biosimilar (IBI305) for advanced hepatocellular carcinoma: A phase Ib clinical trial.
First Author: Wen Zhang
Poster
2018 ASCO Quality Care Symposium
Are real-world patient-reported outcomes associated with survival in patients with advanced pancreatic cancer?
First Author: Wei Fang Dai